Recent advances in understanding and treating Parkinson's disease

Abstract

Background: Neurodegenerative illness that is characterised by the loss of dopaminergic neurons in the substantia nigra. Because its global prevalence keeps going up, there’s a need for fresh, updated synthesis of what’s new in pathophysiology, diagnostics, and treatment options, maybe also how clinicians should think about them. Objective: This review, more or less, aims to look at the current landscape of PD pathophysiology, and then check out emerging diagnostic modalities, then summarise how pharmacological and non-pharmacological treatment strategies are changing. It also tries to include a set of more novel experimental angles, not only the usual stuff. Methods: For the methods, we carried out a narrative review using published literature that covers PD pathogenesis, genetic mutations, diagnostic technologies, and therapeutic interventions. We tried to spot key trends, and then connect those findings with what they might mean for real-world clinical management , over time. Results: In the results section, the big central pathogenic feature is the alpha-synuclein aggregation that forms Lewy bodies. On the genetic side, mutations in SNCA, LRRK2, PARK7, PINK1, and PRKN are tied to familial forms and they help explain molecular disease mechanisms. For diagnostics, progress includes PET and SPECT neuroimaging, along with cerebrospinal fluid markers and blood-based biomarkers, these together support earlier identification and more precise phenotyping. On therapy, levodopa and dopamine agonists are still treated as first-line pharmacological choices; deep brain stimulation, DBS, acts as a useful adjunctive non-pharmacological intervention. Meanwhile, gene therapy and stem cell based approaches are still more investigational, but they look promising for what could come next. Conclusion: So in the end, recent research has pushed forward the understanding of PD pathophysiology a lot, and it also broadened the available diagnostic and therapeutic options. The overall idea is that combining biomarker-guided diagnosis with emerging disease-modifying therapies could really help, and it holds promise for better long-term outcomes in PD patients, though it’s not fully settled yet.